CLDX Stock Overview
A biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Celldex Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$33.47 |
52 Week High | US$53.18 |
52 Week Low | US$22.11 |
Beta | 1.6 |
1 Month Change | -21.36% |
3 Month Change | -33.07% |
1 Year Change | -1.59% |
3 Year Change | 17.44% |
5 Year Change | 1,233.47% |
Change since IPO | -70.76% |
Recent News & Updates
Recent updates
We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth
Jul 07An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued
Apr 21Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth
Feb 27We're Not Very Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Rate
Sep 07Celldex begins dosing in mid-stage study of barzolvolimab for skin disorder
Jul 21Celldex: Barzolvolimab Plus Bispecific Antibodies Advancement
Jul 14Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans
May 25Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 31%?
Feb 03Celldex: Pipeline Of Drug Candidates Is Worth A Look
Feb 01Celldex Therapeutics: A Best Price-Positioned Biotech Stock As Seen By Market-Makers
Sep 23We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth
Sep 15Celldex: Powerful Medicines To Yield Further Upsides
Jul 08Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation
May 12We're Hopeful That Celldex Therapeutics (NASDAQ:CLDX) Will Use Its Cash Wisely
Jan 27The Celldex Therapeutics (NASDAQ:CLDX) Share Price Is Up 626% And Shareholders Are Delighted
Dec 23Dosing underway in Celldex's CDX-0159 study in skin allergy
Dec 09Shareholder Returns
CLDX | US Biotechs | US Market | |
---|---|---|---|
7D | -9.3% | -0.4% | -0.6% |
1Y | -1.6% | 5.4% | 22.5% |
Return vs Industry: CLDX underperformed the US Biotechs industry which returned 5.4% over the past year.
Return vs Market: CLDX underperformed the US Market which returned 22.5% over the past year.
Price Volatility
CLDX volatility | |
---|---|
CLDX Average Weekly Movement | 5.4% |
Biotechs Industry Average Movement | 10.7% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CLDX's share price has been volatile over the past 3 months.
Volatility Over Time: CLDX's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1983 | 160 | Anthony Marucci | www.celldex.com |
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity.
Celldex Therapeutics, Inc. Fundamentals Summary
CLDX fundamental statistics | |
---|---|
Market cap | US$2.19b |
Earnings (TTM) | -US$144.88m |
Revenue (TTM) | US$6.07m |
363.3x
P/S Ratio-15.2x
P/E RatioIs CLDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CLDX income statement (TTM) | |
---|---|
Revenue | US$6.07m |
Cost of Revenue | US$122.87m |
Gross Profit | -US$116.80m |
Other Expenses | US$28.07m |
Earnings | -US$144.88m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -2.20 |
Gross Margin | -1,923.62% |
Net Profit Margin | -2,385.97% |
Debt/Equity Ratio | 0% |
How did CLDX perform over the long term?
See historical performance and comparison